Zachariah Carter

Dr. Zachariah Carter

New England Biolabs (United States), Ipswich, Massachusetts, USA
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2021 in Biophysical Chemistry
Verified
Journal Article
Closed access
ZCZachariah Carter
Zachariah Carter
NSNathaniel W. Scull
Nathaniel W. Scull
DSDavid S. Schneider
David S. Schneider
ALAaron L. Lucius
Aaron L. Lucius

11 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
RJRuth Qian Jacobs
Ruth Qian Jacobs
KFKaila B. Fuller
Kaila B. Fuller
SCStephanie Cooper
Stephanie Cooper
ZCZachariah Carter
Zachariah Carter
MLMarikki Laiho
Marikki Laiho
DSDavid Schneider
David Schneider
Cancer cells require robust ribosome biogenesis to maintain rapid cell growth during tumorigenesis. Because RNA polymerase I (Pol I) transcription of the ribosomal DNA (rDNA) is the first and rate-limiting step of ribosome biogenesis, it has emerged as a promising anti-cancer target. Over the last decade, novel cancer therapeutics targeting Pol I have progressed to clinical trials. BMH-21 is a first-in-class small molecule that inhibits Pol I transcription and represses cancer cell growth. Several recent studies have uncovered key mechanisms by which BMH-21 inhibits ribosome biosynthesis but the selectivity of BMH-21 for Pol I has not been directly measured. Here, we quantify the effects of BMH-21 on Pol I, RNA polymerase II (Pol II), and RNA polymerase III (Pol III) in vitro using purified components. We found that BMH-21 directly impairs nucleotide addition by Pol I, with no or modest effect on Pols II and III, respectively. Additionally, we found that BMH-21 does not affect the stability of any of the Pols’ elongation complexes. These data demonstrate that BMH-21 directly exploits unique vulnerabilities of Pol I.

1 January 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
RJRuth Qian Jacobs
Ruth Qian Jacobs
ZCZachariah Carter
Zachariah Carter
ALAaron L. Lucius
Aaron L. Lucius
DSDavid Schneider
David Schneider
Eukaryotes express at least three nuclear DNA-dependent RNA polymerases (Pols) responsible for synthesizing all RNA required by the cell. Despite sharing structural homology, they have functionally diverged to suit their distinct cellular roles. Although the Pols have been studied extensively, direct comparison of their enzymatic properties is difficult because studies are often conducted under disparate experimental conditions and techniques. Here, we directly compare and reveal functional differences between Saccharomyces cerevisiae Pols I and II using a series of quantitative in vitro transcription assays. We find that Pol I single-nucleotide and multinucleotide addition rate constants are faster than those of Pol II. Pol I elongation complexes are less stable than Pol II elongation complexes, and Pol I is more error prone than Pol II. Collectively, these data show that the enzymatic properties of the Pols have diverged over the course of evolution, optimizing these enzymes for their unique cellular responsibilities.


8 October 2022 in iScience
Verified
Journal Article
Open access
RJRuth Q. Jacobs
Ruth Q. Jacobs
ZCZachariah Carter
Zachariah Carter
ALAaron L. Lucius
Aaron L. Lucius
DSDavid Schneider
David Schneider
Eukaryotes express three nuclear RNA polymerases (Pols I, II, and III) that are essential for cell survival. Despite extensive investigation of the three Pols, significant knowledge gaps regarding their biochemical properties remain because each Pol has been evaluated independently under disparate experimental conditions and methodologies. To advance our understanding of the Pols, we employed identical in vitro transcription assays for direct comparison of their elongation rates, elongation complex (EC) stabilities, and fidelities. Pol I is the fastest, most likely to misincorporate, forms the least stable EC, and is most sensitive to alterations in reaction buffers. Pol II is the slowest of the Pols, forms the most stable EC, and negligibly misincorporated an incorrect nucleotide. The enzymatic properties of Pol III were intermediate between Pols I and II in all assays examined. These results reveal unique enzymatic characteristics of the Pols that provide new insights into their evolutionary divergence.

1 October 2021 in Biophysical Journal
Verified
Journal Article
Closed access
ZCZachariah Carter
Zachariah Carter
DSDavid Schneider
David Schneider
ALAaron L. Lucius
Aaron L. Lucius